Carbamic Acid

Carbamic Acid

SCHEMBL119806

NC(=O)O.c1ccc(COCc2ccccc2)cc1

nearest known ligand 0.71

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 2/20 0.71
ALDH1A1 P00352 3/20 0.54
PARP10 Q53GL7 1/20 0.53
IDO1 P14902 1/20 0.52
KMT2A Q03164 2/20 0.52
MAPK1 P28482 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A3 Q01959 1/20 0.52
TDP1 Q9NUW8 1/20 0.52
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
KDM4E B2RXH2 1/20 0.52
POLB P06746 1/20 0.52
SLC1A1 P43005 3/20 0.51
AGXT P21549 1/20 0.50
ALOX5 P09917 1/20 0.49
SLC1A3 P43003 2/20 0.48
SLC1A2 P43004 2/20 0.48
MEN1 O00255 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Urea SCHEMBL28054623 0.95 TSHR (0.71) TSHRALDH1A1PARP10IDO1KMT2A
Hydroxyamine SCHEMBL1680424 0.87 TSHR (0.83) TSHRALDH1A1IDO1MAPK1L3MBTL1
Benzyl Carbamate SCHEMBL7386720 0.87 TSHR (0.60) TSHRALDH1A1PARP10KMT2AMAPK1
Hydrogen Peroxide SCHEMBL28758135 0.87 TSHR (0.94) TSHRALDH1A1IDO1KMT2AMAPK1
Acetone SCHEMBL28740549 0.86 TSHR (0.71) TSHRALDH1A1KMT2AMAPK1L3MBTL1
Acetic Acid SCHEMBL28710458 0.86 TSHR (0.71) TSHRALDH1A1KMT2AMAPK1L3MBTL1
Acetic Acid SCHEMBL4466285 0.86 TSHR (0.71) TSHRALDH1A1KMT2AMAPK1L3MBTL1
SCHEMBL203767 0.85 TSHR (0.56) TSHRALDH1A1PARP10IDO1KMT2A
SCHEMBL27380 0.84 TSHR (1.00) TSHRALDH1A1IDO1SLC6A2SLC6A3
SCHEMBL5311581 0.84 TSHR (1.00) TSHRALDH1A1IDO1SLC6A2SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2022-02-03 US disclosed
US-20200360521-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2020-11-19 US disclosed
US-9919060-B2 Treatment or prophylaxis of proliferative conditions UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2018-03-20 US disclosed
US-20170368188-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2017-12-28 US disclosed
EP-2857018-A1 Treatment or prophylaxis of proliferative conditions University Court of The University of Dundee (GB) 2015-04-08 EP disclosed
US-20150011512-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2015-01-08 US disclosed
US-20120302748-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-11-29 US disclosed
US-8283340-B2 Treatment or prophylaxis of proliferative conditions The University of the University of Dundee (GB) 2012-10-09 US disclosed
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2012-07-26 US disclosed
CN-102458394-A Treatment or prevention of proliferative conditions UNIV DUNDEE 2012-05-16 CN disclosed
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS THE UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-12-02 US disclosed
WO-2010125350-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS UNIVERSITY COURT OF THE UNIVERSITY OF DUNDEE (GB) 2010-11-04 WO disclosed
US-7102023-B2 Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2006-09-05 US disclosed
US-20040220389-A1 Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2004-11-04 US disclosed
US-6693178-B2 HALOGENATED BENZYL ETHER GALACTOPYRANOSIDE, GLUCOPYRANOSIDE, RIBOFURANOSIDE OR XYLOFURANOSIDE DERIVATIVES; STABLE, EASILY REMOVED MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2004-02-17 US disclosed
US-20030181690-A1 Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2003-09-25 US disclosed
EP-1233970-A2 PROTECTING GROUPS USEFUL IN THE SYNTHESIS OF POLYSACCHARIDES, NATURAL PRODUCTS, AND COMBINATORIAL LIBRARIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2002-08-28 EP disclosed
US-6426421-B1 HALOGENATED BENZYL ETHER-BASED PROTECTING GROUPS FOR FUNCTIONAL GROUPS, OF ALCOHOLS, THIOLS, AMINES, CARBOXYLIC ACIDS, AND PHOSPHORIC ACIDS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 2002-07-30 US disclosed
WO-2001038337-A2 PROTECTING GROUPS USEFUL IN THE SYNTHESIS OF POLYSACCHARIDES, NATURAL PRODUCTS, AND COMBINATORIAL LIBRARIES MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) 2001-05-31 WO disclosed
US-4820718-A PLATELET ACTIVATING FACTOR INHIBITORS SANDOZ PHARM. CORP. (US) 1989-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100305070-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS BRCA1, CYP1B1, UGT1A1 TSHR 3996/4885ALDH1A1 35/4885PARP10 2267/4885
US-20200360521-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 TSHR 4019/4885ALDH1A1 55/4885PARP10 1723/4885
US-20040220389-A1 Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries FUT5, FUT6, UGCG TSHR 2453/4885ALDH1A1 1137/4885PARP10 945/4885
US-20120302748-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS BRCA1, CYP1B1, UGT1A1 TSHR 3996/4885ALDH1A1 35/4885PARP10 2267/4885
US-20120190639-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 TSHR 4019/4885ALDH1A1 55/4885PARP10 1723/4885
US-20220031852-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 TSHR 4019/4885ALDH1A1 55/4885PARP10 1723/4885
US-20030181690-A1 Protecting groups useful in the synthesis of polysaccharides, natural products, and combinatorial libraries FUT5, FUT6, UGCG TSHR 2453/4885ALDH1A1 1137/4885PARP10 945/4885
US-20170368188-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 TSHR 3989/4885ALDH1A1 61/4885PARP10 1447/4885
US-20150011512-A1 TREATMENT OR PROPHYLAXIS OF PROLIFERATIVE CONDITIONS CYP1B1, UGT1A1, CYP1A1 TSHR 4019/4885ALDH1A1 55/4885PARP10 1723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.